

Effective November 1, 2023, refer to CMS Manual 100-02, Chapter 16-General Exclusions from Coverage for services included in this policy.



**BlueCross BlueShield
of Alabama**

Name of Blue Advantage Policy:
Signal-Averaged Electrocardiography

Policy #:318

Latest Review Date: December 2022

Category: Medical

ARCHIVED EFFECTIVE 11/1/2023

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

- 1. Safe and effective;*
- 2. Not experimental or investigational*;*
- 3. Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - Furnished in a setting appropriate to the patient's medical needs and condition;*
 - Ordered and furnished by qualified personnel;*
 - One that meets, but does not exceed, the patient's medical need; and*
 - At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Blue Advantage will treat **signal-averaged electrocardiography** as a **non-covered** benefit and as **investigational**, including, but not limited to:

- its use as a technique of risk stratification for arrhythmias after prior myocardial infarction; or
- in patients with cardiomyopathy; or
- in patients with syncope; or
- as an assessment of success after surgery for arrhythmia; or
- in the detection of acute rejection of heart transplants; or
- as an assessment of efficacy of antiarrhythmic drug therapy; or
- in the assessment of success of pharmacological, mechanical, or surgical interventions to restore coronary artery blood flow.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Signal-averaged electrocardiography (SAECG) is a technique involving computerized analysis of small segments of a standard ECG to detect abnormalities, termed ventricular late potentials (VLPs), that would be otherwise obscured by “background” skeletal muscle activity. VLPs reflect aberrant, asynchronous electrical impulses arising from viable isolated cardiac muscle bordering an infarcted area and are thought to be responsible for ventricular tachyarrhythmias. Therefore, VLPs, as measured by SAECG, have been investigated as a risk factor for arrhythmic events in patients with a variety of cardiac conditions, including cardiomyopathy and prior history of myocardial infarction (MI). Patients considered at high risk of ventricular arrhythmias and thus sudden death may be treated with drugs to suppress the emergence of arrhythmias or implantable cardiac defibrillators (ICD) to promptly detect and terminate tachyarrhythmias when they occur. Because sudden cardiac death, whether from arrhythmias or pump failure, is one of the most common causes of death after a previous myocardial infarction, there is intense interest in risk stratification to target therapy. Patient groups are divided into those who have not experienced a life-threatening arrhythmia (i.e., primary prevention) and those who have (i.e., secondary prevention). SAECG is just one of many risk factors that have been investigated. Others include left ventricular ejection fraction (LVEF), arrhythmias detected on Holter monitor or electrophysiologic studies, heart rate variability, and baroreceptor sensitivity. T-wave alternans is another technique for risk stratification; it measures beat-to-beat variability, while SAECG measures beat-averaged conduction.

KEY POINTS:

The most recent update of this policy includes a literature review through December 14, 2022.

Summary

For individuals receiving signal averaged electrocardiography, the evidence includes prospective studies, small comparative studies, and retrospective reviews. Relevant outcomes are overall survival, morbid events, and treatment related morbidity. Signal-averaged ECG has some ability to risk-stratify patients at risk for ventricular arrhythmias. However, this predictive ability is modest, and this technique has not been used to stratify patients into clinically relevant categories of risk. Some RCTs have used signal-averaged ECG for selection of patients at high risk of ventricular arrhythmias, but these studies have not demonstrated outcome benefits for the treatments under study. Signal-averaged ECG has also been tested as a diagnostic test for a variety of cardiac-related disorders, but the evidence is insufficient to demonstrate clinical utility for any of the conditions tested. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements**American Heart Association**

The American Heart Association, American College of Cardiology Foundation, and Heart Rhythm Society published a scientific statement in 2008 that included signal averaged ECG. They conclude that “routine use of SAECG to identify patients at high risk for SCD is not adequately supported...”

KEY WORDS:

Electrocardiography, Signal-Averaged, SAECG, Signal-Averaged Electrocardiography

APPROVED BY GOVERNING BODIES:

Not applicable

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:**CPT Codes:**

93278	Signal-Averaged Electrocardiography (SAECG), With or without ECG
-------	--

REFERENCES:

1. Bailey JJ, Berson AS, Handelsman H et al. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. *J Am Coll Cardiol* 2001; 38(7):1902-11.
2. Bauer A, Guzik P, Barthel P et al. Reduced prognostic power of ventricular late potential in post-infarction patients of the reperfusion era. *Eur Heart J* 2005; 26(8):755-61.
3. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. *Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med* 1997; 337(22):1569-75.
4. Cain ME, Anderson JL, Arnsdorf MF et al. ACC expert consensus document. Signal-averaged electrocardiography. *J Am Coll Cardiol* 1996; 27(1):238-49.
5. Cairns JA, Connolly SJ, Roberts R et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization: CAMIAT. *Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet* 1997; 349(9053):675-82.
6. Dinov B, Bode K, Koenig S, et al. Signal-averaged electrocardiography as a noninvasive tool for evaluating the outcomes after radiofrequency catheter ablation of ventricular tachycardia in patients with ischemic heart disease: Reassessment of an old tool. *Circ Arrhythm Electrophysiol.* 2016;9(9).
7. Dinov B, Schramm L, Koenig S, et al. Dynamic changes in the signal-averaged electrocardiogram are associated with the long-term outcomes after ablation of ischemic ventricular tachycardia. *J Interv Card Electrophysiol.* 2021;60(1):125-134.
8. Furukawa Y, Yamada T, Okuyama Y et al. Increased intraatrial conduction abnormality assessed by P-wave signal-averaged electrocardiogram in patients with Brugada syndrome. *Pacing Clin Electrophysiol* 2011; 34(9):1138-46.
9. Goldberger JJ, Cain FM, Hohnloser SH et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. *J Am Coll Cardiol* 2008; 52:1179-99.
10. Gregoratos G, Cheitlin MD, Conill A et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). *J Am Coll Cardiol* 1998; 31(5):1175-209.
11. Grimm W, Christ M, Bach J et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. *Circulation* 2003; 108(23):2883-91.
12. Hohnloser SH, Klingenhoben T, Zabel M. Identification of patients after myocardial infarction at risk of life-threatening arrhythmias. *Eur Heart J* 1999; 1(suppl C):C11-20.
13. Huikuri HV, Tapanainen JM, Lindgren K et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. *J Am Coll Cardiol* 2003; 42(4):652-8.
14. IOM (Institute of Medicine). 2011. *Clinical Practice Guidelines We Can Trust*. Washington, DC: The National Academies Press.

15. Julian DG, Camm AJ, Frangin G et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 439(9053):667-74.
16. Kamath GS, Zareba W, Delaney J et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8(2):256-62.
17. Liao YC, Chung FP, Lin YJ, et al. The application of signal average ECG in the prediction of recurrences after catheter ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Int J Cardiol. 2017;236:168-173.
18. Militaru C, Donoiu I, Ionescu DD. PWave Signal-Averaged ECG in Normal Population and in Patients with Converted Atrial Fibrillation. Ann Noninvasive Electrocardiol 2011; 16(4):351-6.
19. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335(26):1933-40.
20. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12):877-83.
21. Nagamoto Y, Fujii Y, Morita Y, et al. Atrial electrical abnormality in patients with Brugada syndrome assessed by signal-averaged electrocardiography. Indian Heart J. 2017;69(6):714-719.
22. Rejdak K, Rubaj A, Glowinski A et al. Analysis of ventricular late potentials in signal-averaged ECG of people with epilepsy. Epilepsia 2011; 52(11):2118-24.
23. Schuller JL, Lowery CM, Zipse M et al. Diagnostic utility of signal-averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011; 16(1):70-6.
24. Shturman A, Bickel A, Atar S. The predictive value of P-wave duration by signal-averaged electrocardiogram in acute ST elevation myocardial infarction. The Israel Medical Association Journal IMAJ 2012;14(8):493-7.
25. Toubol P. A decade of clinical trials; CAST to AVID. Eur Heart J 1999; 1(suppl C):C2-10.
26. U.S. Department of Health and Human Services. Health Technology Assessment. Number 11. Signal-averaged electrocardiography. 1998. Publication No. PB98-137227.
27. Ueno A, Kobayashi Y, Yodogawa K et al. A prospective study on the risk-stratification for patients with non-sustained ventricular tachycardia using a novel algorithm. Circ J 2007; 71(7):107-14.
28. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice

Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006; 114(10):1088-132.

POLICY HISTORY:

Adopted for Blue Advantage, March 2011

Available for comment April 4 – May 18, 2011

Medical Policy Group, February 2012

Medical Policy Group, January 2013

Medical Policy Group, November 2019

Medical Policy Group, December 2020

Medical Policy Group, January 2022: Reviewed by consensus. No new published peer-reviewed literature available that would alter the coverage statement in this policy.

Medical Policy Group, December 2022: Reviewed by consensus. No new published peer-reviewed literature available that would alter the coverage statement in this policy.

Medical Policy Group, November 2023: Archived effective 11/1/2023.

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.